3Connolly SJ. Preventing stroke in patients with atrial fibrillation: current treat- ments and new concepts[J]. Am Heart J,2003,145(3) :418-423.
4Holmes D. ACC & i2 Summit 2009. PROTECT AF Trial.
5Crystal E, Connolly SJ. Role of oral antlcoagulation in management of atrial fibrillation[J]. Heart, 2004,90(7) :813-817.
6Atrial Fibrillation Investigators. Risk factor and efficacy of antithrobotic therapy in atrial fibrillation[J].Arch Intern Med, 1998,97 : 1231-1233.
7Donal E, Yamada H, Leciercq C, et al. The left atrial appendage, a small, blind-ended structure : a review of its echoeardiographic evaluation and its clinical role [J].Chest,2005,128 (3) : 1853-1862.
8Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation[J]. J Am Coll Cardiol, 2007 ,49(13):1490-1495.
9Su P, McCarthy KP, Ho SY. Occluding the left atrial appendage: anatomical considerations [ J ]. Heart, 2008 ,94 ( 9 ) : 1166-1170.
10Klein AL, Grimm RA, Black IW, et al. Cardioversion guided by transesophageal echocardiography: the ACUTE Pilot Study. A randomized, controlled trial. Assessment of Cardioversion Using Transesophageal Echocardiography[ J]. Ann Intern Meal, 1997,126(3) :200-209.
